GlassScriptPhysician profile
Shen Song
NPI 1518386911
$2,173.36
in general payments reported to CMS, 2019-2025
20 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $234 · 2023: $75.09 · 2024: $865 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $295.07 | 2022-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $288.49 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $273.26 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $165.44 | 2021-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $158.86 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $140.40 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $130.53 | 2022-2025 | |
| Vifor Pharma, INC. | $121.99 | 2021-2024 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.97 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $74.51 | 2024-2025 | Rivfloza, Ozempic |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $71.52 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $71.39 | 2024-2025 | Velphoro, Velphoro |
| Lilly USA, LLC | $56.74 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $51.40 | 2024 | Acthar |
| Ardelyx, INC. | $43.00 | 2024-2025 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $29.87 | 2025 | Vafseo |
| Travere Therapeutics, INC. | $28.38 | 2024 | |
| Scpharmaceuticals INC. | $27.93 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.95 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $20.66 | 2025 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shen Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.